Key terms
About NVCR
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NVCR news
Apr 05
7:03am ET
Novocure announces 20 presentations at AACR 2024
Apr 03
6:28am ET
Novocure price target lowered to $42 from $49 at Wells Fargo
Apr 02
7:05pm ET
NovoCure (NVCR) Receives a Buy from Wells Fargo
Mar 29
3:06am ET
NovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Target
Mar 28
5:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
5:01am ET
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
Mar 27
11:45am ET
Nuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s Stock
Mar 27
11:37am ET
Novocure METIS results ‘not a home run,’ says H.C. Wainwright
Mar 27
9:41am ET
NovoCure trading resumes
Mar 27
9:36am ET
NovoCure trading halted, volatility trading pause
Mar 27
9:36am ET
Zai Lab says partner Novocure’s Phase 3 trial met primary endpoint
Mar 27
7:49am ET
Novocure spikes 30% after drug trial met primary endpoint
Mar 27
7:08am ET
Novocure: METIS Phase 3 clinical trial met primary endpoint in NSCLC study
Mar 19
8:20am ET
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), CareMax (CMAX) and NovoCure (NVCR)
Mar 12
10:35am ET
NovoCure’s Clinical Trial Results: Subgroup Promise Amidst Cautioned Market Outlook
Feb 25
11:28pm ET
Buy Rating Affirmed for NovoCure Amid Strong Q4 Performance and Promising Pipeline Developments
Feb 23
7:33am ET
Piper Sandler Sticks to Its Buy Rating for NovoCure (NVCR)
Feb 23
6:00am ET
Buy Rating Affirmed for NovoCure Amid Positive Clinical Results and Solid Financial Performance
Feb 22
12:15pm ET
Novocure price target raised to $22 from $21 at H.C. Wainwright
Feb 22
9:38am ET
NovoCure trading resumes
Feb 22
9:33am ET
NovoCure trading halted, volatility trading pause
Feb 22
7:05am ET
Novocure reports Q4 EPS (45c), consensus (52c)
Jan 19
3:04am ET
NovoCure’s Lung Cancer Therapy Application Accepted by FDA
Jan 18
7:09am ET
FDA accepts Novocure PMA application for TTFields therapy in NSCLC
Jan 12
7:37am ET
Piper Sandler Sticks to Their Buy Rating for NovoCure (NVCR)
Jan 09
7:15am ET
Novocure enrolls final patient in TRIDENT clinical trial
Jan 09
6:33am ET
NovoCure’s Hold Rating: Balancing Near-Term Challenges with Long-Term Market Potential
Jan 09
5:14am ET
NovoCure’s Strong Q4 Performance and Promising Pipeline Underpin Buy Rating
Jan 08
7:22am ET
Novocure sees FY23 revenue $509.3M, consensus $505.05M
Jan 08
7:19am ET
Novocure reports preliminary Q4 revenue $133.8M, consensus $129.3M
Jan 08
7:19am ET
Novocure reports preliminary Q4 revenue $133.8M, consensus $129.3M
No recent press releases are available for NVCR
NVCR Financials
Key terms
Ad Feedback
NVCR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NVCR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
